Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Other Accumulated Expenses: 2023-2025

Historic Other Accumulated Expenses for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $141,000.

  • Compass Therapeutics' Other Accumulated Expenses fell 15.57% to $141,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $141,000, marking a year-over-year decrease of 15.57%. This contributed to the annual value of $621,000 for FY2024, which is 158.75% up from last year.
  • Compass Therapeutics' Other Accumulated Expenses amounted to $141,000 in Q3 2025, which was down 63.28% from $384,000 recorded in Q2 2025.
  • Over the past 5 years, Compass Therapeutics' Other Accumulated Expenses peaked at $621,000 during Q4 2024, and registered a low of $137,000 during Q1 2023.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $274,000 (2025), whereas its average is $290,818.
  • Over the last 5 years, Compass Therapeutics' Other Accumulated Expenses had its largest YoY gain of 158.75% in 2024, and its largest YoY loss of 57.29% in 2024.
  • Quarterly analysis of 3 years shows Compass Therapeutics' Other Accumulated Expenses stood at $240,000 in 2023, then soared by 158.75% to $621,000 in 2024, then declined by 15.57% to $141,000 in 2025.
  • Its Other Accumulated Expenses stands at $141,000 for Q3 2025, versus $384,000 for Q2 2025 and $274,000 for Q1 2025.